Floatz logo

ASCRINVACUMAB

Neoplasms

Suzhou Kintor Pharmaceutical Inc,monoclonal_antibodyPhase 1/2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
65/ 100

Competitive context

927 Active assets in the Neoplasms cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

ASCRINVACUMAB is also rated in:

HCCDormant
B
Indicative ·
61 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
61 / 100
View asset →
substance dependenceDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →